http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108623694-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 |
| filingDate | 2017-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108623694-B |
| titleOfInvention | Derivative of vascular endothelial cell growth factor receptor antagonistic peptide F56 and application thereof |
| abstract | The invention provides a derivative of vascular endothelial cell growth factor receptor antagonistic peptide F56 and application thereof, wherein the derivative of the vascular endothelial cell growth factor receptor antagonistic peptide F56 is a peptide derivative formed by connecting MIPA-AEEA-group on the basis of the structure of the vascular endothelial cell growth factor receptor antagonistic peptide F56. The peptide derivative has the functions of keeping the combination of the antagonistic vascular endothelial cell growth factor (VEGF) of F56 and the receptor 1(VEGFR1) thereof, and has the anti-angiogenesis and anti-tumor activities, and the action time of the peptide derivative is obviously prolonged compared with the action time of the polypeptide F56, so that the peptide derivative can be used for anti-angiogenesis and anti-tumor treatment. |
| priorityDate | 2017-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 126.